CorVista System with PH Add-On vs Tempus ECG-AF
AI Verdict
Choose CorVista System with PH Add-On if…
Choose the CorVista System with PH Add-On if you require a rapid, non-invasive, point-of-care diagnostic solution for the immediate assessment of coronary artery disease and pulmonary hypertension. This tool is ideal for situations where avoiding radiation, contrast agents, or exercise is crucial, and quick results are needed to inform urgent clinical decisions.
View CorVista System with PH Add-On →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your goal is to proactively identify patients aged 65 or older who are at increased risk of developing new-onset atrial fibrillation within the next 12 months. This AI-based algorithm integrates seamlessly with existing 12-lead ECG workflows to support early identification and enable timely follow-up for preventative management.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | CorVista System with PH Add-On | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Cloud-based, point-of-care system. | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CorVista System with PH Add-OnTool A, the CorVista System, emphasizes a non-invasive, point-of-care approach that requires no radiation, contrast agents, injections, fasting, or exercise, with rapid results available within minutes via a secure web portal. This significantly enhances the patient experience and streamlines the diagnostic workflow for clinicians.
Clinical Value
CorVista System with PH Add-OnBoth tools are FDA-cleared, demonstrating clinical utility. However, Tool A provides a rapid, non-invasive diagnostic assessment for *existing* coronary artery disease and pulmonary hypertension, addressing immediate clinical needs for symptomatic patients. Tool B offers a valuable *predictive* risk assessment for future atrial fibrillation, but Tool A's broader and more direct diagnostic capability for two major conditions provides more immediate clinical impact.
Pricing & Value
Tempus ECG-AFTool B, Tempus ECG-AF, explicitly details CMS reimbursement availability with specific CPT codes and a Medicare rate, offering a clear and tangible financial value proposition for healthcare providers. In contrast, Tool A's pricing information is only available upon contact, lacking transparency regarding its economic value.
Enterprise Readiness
Tempus ECG-AFTool B explicitly states 'yes' for both HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are critical assurances for healthcare organizations adopting new technologies. While Tool A is 'likely' compliant, the definitive statements from Tempus provide greater confidence for enterprise integration and data handling.
Innovation
CorVista System with PH Add-OnTool A introduces a highly innovative, non-invasive, point-of-care diagnostic platform that analyzes cardiac and hemodynamic signals without the need for traditional, often burdensome, diagnostic procedures like radiation or injections. This represents a more significant paradigm shift in diagnostic methodology compared to Tool B, which applies AI to existing 12-lead ECG data for predictive risk assessment.
Support & Docs
Tempus ECG-AFTempus (Tool B) provides clear and accessible customer support channels, including phone, email, and live chat, with specified business hours and response times, and also mentions a document library. For CorVista System (Tool A), specific public information regarding customer support contacts or comprehensive documentation portals was not readily available through web searches.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CorVista System with PH Add-On | Tempus ECG-AF |
|---|---|---|
| Tool Name | CorVista System with PH Add-On | Tempus ECG-AF |
| Company | Analytics for Life | Tempus AI, Inc. |
| Primary Diagnostic/Identification Focus | Rapid assessment of coronary artery disease and pulmonary hypertension. | Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Input Data Type | Cardiac and hemodynamic signals (non-invasive, no radiation, contrast agents, injections, fasting, or exercise required). | 12-lead ECG recordings. |
| Target Patient Population/Conditions | Patients requiring assessment for coronary artery disease and pulmonary hypertension. | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| Reimbursement Information | Not specified | CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). |
Videos
Demos, reviews, and walkthroughs featuring CorVista System with PH Add-On and Tempus ECG-AF.
Frequently Asked Questions
More Comparisons
More matchups featuring CorVista System with PH Add-On or Tempus ECG-AF
Backers
Who funded each tool's parent company.